Physician profile
John G Mathis
NPI 1427051341
$16,232.17
in general payments reported to CMS, 2019-2025
44 companies · $2,277 in 2025
The $2,277 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,036 · 2020: $1,176 · 2021: $2,363 · 2022: $2,686 · 2023: $2,482 · 2024: $3,212 · 2025: $2,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,669 · Travel and Lodging: $291 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,668.93 |
| Travel and Lodging | $291.33 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,660.50 | 2019-2025 | |
| Janssen Biotech, INC. | $1,866.68 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $1,647.21 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,173.80 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $1,094.26 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $542.33 | 2022-2025 | Dupixent |
| Celgene Corporation | $453.64 | 2022-2024 | Zeposia |
| Boston Scientific Corporation | $445.91 | 2019-2024 | Exalt Model D, Watchman Flx |
| Pfizer INC. | $409.17 | 2019-2025 | |
| Genzyme Corporation | $403.36 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $400.54 | 2019-2023 | Dificid |
| Mauna Kea Technologies, INC. | $331.30 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $294.04 | 2020-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $254.57 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $236.53 | 2021-2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $230.89 | 2022-2025 | Concertotm, Gi Genius |
| Shionogi INC | $191.31 | 2019-2020 | |
| Braintree Laboratories, INC. | $187.99 | 2019-2023 | Suflave, Sutab |
| Amgen INC. | $143.28 | 2020-2025 | |
| Intercept Pharmaceuticals, INC. | $123.20 | 2019-2024 | |
| Madrigal Pharmaceuticals | $120.51 | 2024-2025 | Resmetirom, Rezdiffra |
| Lilly USA, LLC | $118.16 | 2023-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $100.00 | 2019 | |
| Covidien LP | $97.38 | 2020 | |
| Organon LLC | $75.07 | 2023-2024 | Renflexis |
| Ferring Pharmaceuticals INC. | $65.58 | 2020-2023 | Rebyota |
| Qol Medical, LLC | $61.55 | 2023-2024 | Sucraid, Sucraid |
| Allergan, INC. | $51.45 | 2019-2020 | |
| Daiichi Sankyo INC. | $49.34 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.37 | 2023-2024 | Cyltezo |
| Sirtex Medical INC | $39.97 | 2024-2025 | Sir-Spheres Microspheres |
| Vivus LLC | $37.26 | 2022-2025 | Pancreaze |
| Ipsen Biopharmaceuticals, INC | $37.10 | 2024-2025 | Iqirvo |
| Ucb, INC. | $35.23 | 2019 | |
| Alnylam Pharmaceuticals INC. | $35.18 | 2021-2022 | |
| Alfasigma USA, INC. | $31.15 | 2020 | |
| Aimmune Therapeutics, INC. | $26.27 | 2024 | |
| Dova Pharmaceuticals | $19.84 | 2019 | |
| Pharmacosmos Therapeutics INC. | $18.74 | 2023 | Monoferric |
| Ardelyx, INC. | $17.68 | 2024 | Ibsrela |
| Redhill Biopharma INC. | $16.85 | 2021 | |
| Shire North American Group INC | $16.51 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $15.99 | 2025 | Blueboost |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.